We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

156 hedge funds and large institutions have $1.02B invested in Revance Therapeutics, Inc. in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 59 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

176% more call options, than puts

Call options by funds: $27.5M | Put options by funds: $9.97M

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

23% more capital invested

Capital invested by funds: $827M → $1.02B (+$188M)

3% more funds holding

Funds holding: 151 → 156 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

22% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 59

Holders
156
Holders Change
+5
Holders Change %
+3.31%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
23
Increased
46
Reduced
59
Closed
17
Calls
$27.5M
Puts
$9.97M
Net Calls
+$17.5M
Net Calls Change
+$15.6M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$9.2M
2
Franklin Resources
Franklin Resources
California
+$5.96M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.89M
4
HighTower Advisors
HighTower Advisors
Illinois
+$4.03M
5
Jennison Associates
Jennison Associates
New York
+$3.61M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$10.5M
2
Capital World Investors
Capital World Investors
California
-$5.49M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$2.56M
4
Goldman Sachs
Goldman Sachs
New York
-$2.27M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$7.07M -$44.1K -2,911 -0.8%
Wellington Management Group
27
Wellington Management Group
Massachusetts
$6.72M -$10.5M -694,124 -67%
PPA
28
Parametric Portfolio Associates
Washington
$5.41M -$1.37M -90,482 -25%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$5.35M -$25.9K -1,705 -0.6%
RCAMU
30
Rothschild & Co Asset Management US
Connecticut
$4.34M -$1.01M -66,716 -23%
Invesco
31
Invesco
Georgia
$4.26M +$2.71M +178,955 +454%
Voloridge Investment Management
32
Voloridge Investment Management
Florida
$4.03M -$186K -12,238 -6%
State of New Jersey Common Pension Fund D
33
State of New Jersey Common Pension Fund D
New Jersey
$3.9M +$3.03M +200,094 New
RPAM
34
Rhenman & Partners Asset Management
Sweden
$3.87M +$3.01M +198,358 New
BC
35
Brookfield Corp
Ontario, Canada
$3.84M +$2.99M +197,123 New
ETCM
36
Evolutionary Tree Capital Management
Virginia
$3.44M -$1.09M -72,197 -29%
GIM
37
Granahan Investment Management
Massachusetts
$3.15M -$831K -54,802 -25%
Swiss National Bank
38
Swiss National Bank
Switzerland
$3.14M +$179K +11,800 +8%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$2.88M +$1.52M +100,134 +212%
AllianceBernstein
40
AllianceBernstein
Tennessee
$2.81M +$3.03K +200 +0.1%
PA
41
Perceptive Advisors
New York
$2.68M +$2.09M +137,514 New
Prudential Financial
42
Prudential Financial
New Jersey
$2.65M +$799K +52,674 +63%
Ameriprise
43
Ameriprise
Minnesota
$2.64M +$211K +13,888 +11%
Millennium Management
44
Millennium Management
New York
$2.6M +$2.02M +133,479 New
Marshall Wace
45
Marshall Wace
United Kingdom
$2.39M +$1.86M +122,598 New
Assenagon Asset Management
46
Assenagon Asset Management
Luxembourg
$2.38M +$51.5K +3,395 +3%
Two Sigma Investments
47
Two Sigma Investments
New York
$2.13M +$312K +20,590 +23%
Wells Fargo
48
Wells Fargo
California
$2.02M -$1.01M -66,809 -39%
Jane Street
49
Jane Street
New York
$1.96M +$1.07M +70,636 +238%
Dimensional Fund Advisors
50
Dimensional Fund Advisors
Texas
$1.91M -$509K -33,532 -25%
1
2
3 4 5

RVNC Hedge Fund Activity: Q1 2022 in Review

156 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2022, worth a combined $1.02B — up 23% from $827M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new RVNC positions and 17 closed out — a net gain of 6 holders — while 46 added to existing stakes and 59 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $9.2M. The largest seller was Wellington Management Group, cutting an estimated $10.5M.

  • 156 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2022, up from 151 in Q4 2021.
  • Funds reported $1.02B of Revance Therapeutics, Inc. stock for Q1 2022, up 23% quarter-over-quarter.
  • 23 funds opened new Revance Therapeutics, Inc. positions in Q1 2022 and 17 closed out, a net change of +6 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q1 2022 was Citadel Advisors, an estimated $9.2M added.
  • The largest Revance Therapeutics, Inc. seller in Q1 2022 was Wellington Management Group, an estimated $10.5M sold.

Based on aggregated 13F filings for Q1 2022.